Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

Ítems similars

• Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP
  per: Cummings, J, et al.
  Publicat: (2006)
• A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
  per: Dean, E J, et al.
  Publicat: (2010)
• XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34(+)38(−) cells in a phase 1/2 study of patients with relapsed/refractory AML
  per: Carter, Bing Z., et al.
  Publicat: (2011)
• Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia
  per: Schimmer, Aaron D., et al.
  Publicat: (2009)
• Elevated XIAP expression alone does not confer chemoresistance
  per: Seeger, J M, et al.
  Publicat: (2010)